ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
shemara
|
284 |
81K |
3 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
284
|
81K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Webinar 17/06/24
|
|
shemara
|
25 |
7.4K |
3 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
25
|
7.4K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Webinar 17/06/24
|
|
shemara
|
25 |
7.4K |
3 |
17/06/24 |
17/06/24 |
ASX - By Stock
|
25
|
7.4K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
shemara
|
455 |
166K |
13 |
12/06/24 |
12/06/24 |
ASX - By Stock
|
455
|
166K
|
13
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
shemara
|
17 |
4.6K |
4 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
17
|
4.6K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
shemara
|
61 |
23K |
2 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
61
|
23K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
shemara
|
61 |
23K |
2 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
61
|
23K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
shemara
|
61 |
23K |
6 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
61
|
23K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
shemara
|
890 |
355K |
1 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
890
|
355K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
shemara
|
455 |
166K |
5 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
455
|
166K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: US patent allowed for CHM 0201 (CORE-NK) technology
|
|
shemara
|
15 |
6.3K |
5 |
08/04/24 |
08/04/24 |
ASX - By Stock
|
15
|
6.3K
|
5
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Final Director's Interest Notice MB
|
|
shemara
|
16 |
6.3K |
1 |
07/04/24 |
07/04/24 |
ASX - By Stock
|
16
|
6.3K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
shemara
|
455 |
166K |
0 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
455
|
166K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
shemara
|
73 |
27K |
9 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
73
|
27K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
biotech could be sector for 2024
|
|
shemara
|
10 |
4.6K |
0 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
10
|
4.6K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
biotech could be sector for 2024
|
|
shemara
|
10 |
4.6K |
6 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
10
|
4.6K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
shemara
|
890 |
355K |
2 |
24/02/24 |
24/02/24 |
ASX - By Stock
|
890
|
355K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
shemara
|
34 |
11K |
2 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
34
|
11K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Completion of Entitlement Offer
|
|
shemara
|
44 |
13K |
2 |
07/12/23 |
07/12/23 |
ASX - By Stock
|
44
|
13K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Results of Annual General Meeting
|
|
shemara
|
12 |
4.2K |
1 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
12
|
4.2K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM secures up to A$12.6m through SPP and placements
|
|
shemara
|
18 |
8.7K |
3 |
24/06/23 |
24/06/23 |
ASX - By Stock
|
18
|
8.7K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Share purchase plan completed
|
|
shemara
|
11 |
2.5K |
2 |
23/06/23 |
23/06/23 |
ASX - By Stock
|
11
|
2.5K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Charting Only
|
|
shemara
|
455 |
166K |
6 |
18/05/23 |
18/05/23 |
ASX - By Stock
|
455
|
166K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
How's the Capital Raise Going to Work?
|
|
shemara
|
138 |
46K |
3 |
02/05/23 |
02/05/23 |
ASX - By Stock
|
138
|
46K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Completion of Viral Vector Manufacturing for Phase 1 trial
|
|
shemara
|
16 |
6.6K |
2 |
17/04/23 |
17/04/23 |
ASX - By Stock
|
16
|
6.6K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM to host CAR T Cell Therapies Educational Webinar
|
|
shemara
|
13 |
5.5K |
3 |
11/04/23 |
11/04/23 |
ASX - By Stock
|
13
|
5.5K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
shemara
|
890 |
355K |
4 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
890
|
355K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
How's the Capital Raise Going to Work?
|
|
shemara
|
138 |
46K |
2 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
138
|
46K
|
2
|
|
Charts
|
IMU Biotech |
Re:
IMUGENE CHART. TA only
|
|
shemara
|
35K |
17M |
0 |
10/03/23 |
10/03/23 |
Charts
|
35K
|
17M
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHIMERIC RECEIVES $3.06M R&D TAX INCENTIVE
|
|
shemara
|
35 |
12K |
3 |
20/02/23 |
20/02/23 |
ASX - By Stock
|
35
|
12K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Appendix 4E and Preliminary Final Report
|
|
shemara
|
23 |
8.8K |
2 |
05/09/22 |
05/09/22 |
ASX - By Stock
|
23
|
8.8K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Licenses viral vector technology from Penn for CDH17
|
|
shemara
|
30 |
12K |
2 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
30
|
12K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: A$30 million Equity Placement Agreement with L1 Capital
|
|
shemara
|
43 |
17K |
3 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
43
|
17K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: A$30 million Equity Placement Agreement with L1 Capital
|
|
shemara
|
43 |
17K |
4 |
11/06/22 |
11/06/22 |
ASX - By Stock
|
43
|
17K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
181K |
3 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
380
|
181K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
shemara
|
890 |
355K |
4 |
03/06/22 |
03/06/22 |
ASX - By Stock
|
890
|
355K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Exclusive option exercised for CORE-NK platform
|
|
shemara
|
11 |
4.2K |
2 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
11
|
4.2K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Exclusive option exercised for CORE-NK platform
|
|
shemara
|
11 |
4.2K |
2 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
11
|
4.2K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
181K |
2 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
380
|
181K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Exclusive option exercised for CORE-NK platform
|
|
shemara
|
11 |
4.2K |
2 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
11
|
4.2K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Exclusive option exercised for CORE-NK platform
|
|
shemara
|
11 |
4.2K |
0 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
11
|
4.2K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Exclusive option exercised for CORE-NK platform
|
|
shemara
|
11 |
4.2K |
1 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
11
|
4.2K
|
1
|
|
ASX - By Stock
|
PCK |
Re:
PainChek General Discussion
|
|
shemara
|
20K |
16M |
2 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
20K
|
16M
|
2
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
181K |
1 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
380
|
181K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
181K |
2 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
380
|
181K
|
2
|
|
ASX - By Stock
|
RAD |
Re:
Ann: Change of Director's Interest Notice - RC
|
|
shemara
|
2 |
1.2K |
2 |
12/04/22 |
12/04/22 |
ASX - By Stock
|
2
|
1.2K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
My analysis and intrinsic value of CHM March 2022
|
|
shemara
|
13 |
5.4K |
8 |
27/03/22 |
27/03/22 |
ASX - By Stock
|
13
|
5.4K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CDH17 CAR T PRECLINICAL DATA FEATURED IN NATURE CANCER
|
|
shemara
|
19 |
8.8K |
6 |
23/03/22 |
23/03/22 |
ASX - By Stock
|
19
|
8.8K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Trading Halt
|
|
shemara
|
11 |
4.0K |
3 |
23/03/22 |
23/03/22 |
ASX - By Stock
|
11
|
4.0K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
shemara
|
380 |
181K |
4 |
28/02/22 |
28/02/22 |
ASX - By Stock
|
380
|
181K
|
4
|
|